Free tool
FAERS Monitor: Onureg
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214120 or its brand name (Onureg, Azacitidine). Reports on generic versions are filed under their own applications.
Reports
19,441
Serious
18,487
95% of reports
Hospitalization
8,608
Death reported
6,234
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia2,064
- death1,974
- off label use1,760
- myelosuppression1,700
- neutropenia1,480
- acute myeloid leukaemia1,334
- pneumonia1,096
- thrombocytopenia1,084
- pyrexia1,047
- drug ineffective1,039
- anaemia889
- infection715
- sepsis678
- pancytopenia667
- platelet count decreased660
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 5 |
| 2008 | 16 |
| 2009 | 43 |
| 2010 | 86 |
| 2011 | 119 |
| 2012 | 91 |
| 2013 | 78 |
| 2014 | 278 |
| 2015 | 404 |
| 2016 | 322 |
| 2017 | 670 |
| 2018 | 754 |
| 2019 | 942 |
| 2020 | 1,167 |
| 2021 | 2,108 |
| 2022 | 2,812 |
| 2023 | 2,617 |
| 2024 | 2,512 |
| 2025 | 2,648 |
| 2026 | 1,764 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,718 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute myeloid leukaemiaSignal | 1,334 | 101.2 | 95.8 | 120,988 |
| myelosuppressionSignal | 1,700 | 53.5 | 51.1 | 83,612 |
| febrile neutropeniaSignal | 2,064 | 34.7 | 33.3 | 65,649 |
| pancytopeniaSignal | 667 | 13.1 | 12.1 | 7,345 |
| neutropeniaSignal | 1,480 | 11.9 | 11.3 | 14,692 |
| thrombocytopeniaSignal | 1,084 | 10.6 | 10.0 | 9,353 |
| platelet count decreasedSignal | 660 | 6.7 | 6.2 | 3,214 |
| sepsisSignal | 678 | 6.6 | 6.1 | 3,220 |
| infectionSignal | 715 | 5.4 | 5.0 | 2,541 |
| anaemiaSignal | 889 | 5.1 | 4.7 | 2,906 |
| pneumoniaSignal | 1,096 | 3.7 | 3.5 | 2,154 |
| pyrexiaSignal | 1,047 | 3.3 | 3.1 | 1,680 |
| deathSignal | 1,974 | 2.5 | 2.4 | 1,816 |
| off label useSignal | 1,760 | 2.2 | 2.1 | 1,165 |
| drug ineffective | 1,039 | 0.9 | 0.8 | 28 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.